1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

15 Jun 2022
Admin
News Article

Nrx Pharma Enrolls First Patient In Phase Ii Study Of Bipolar Depression With Sub-Acute Suicidality

Nrx Pharmaceuticals, Inc., A Clinical-Stage, Biopharmaceutical Company, Announced That The First Patient Has Been Enrolled In One Of The Two Psychiatry Studies That It Plans To Initiate This Year: This First Trial Is Studying Patients With Bipolar Depression And Sub-Acute Suicidality (Not Requiring Hospitalization). In The Second Half Of This Year, Nrx Pharmaceuticals Expects To Initiate A Phase Iib/Iii Registrational Trial In Patients With Bipolar Depression And Acute Suicidal Ideation And Behaviour (Asib), Which Requires Hospitalization Of The Patient. The Us Food And Drug Administration (Fda) Previously Awarded Breakthrough Therapy Designation For Nrx-101 For This Last Indication, Based On Positive Phase Ii Data That The Company Submitted.Nrx-101 Is An Oral, Patented, Fixed-Dose Combination Product Of D-Cycloserine And Lurasidone. D-Cycloserine Exhibits Partial Nmda Receptor Antagonist Activity At Specific Dosages. Both Components Are Approved Drugs That Are Not Scheduled, As Available Data Has Not Shown Potential For Abuse. This Is Important

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!